Novo Nordisk (Ozempic)

8591.152 - 8618.286 Ben Gilbert

Yep, that is pretty crazy. David, you mentioned it as the GLP-1 company already, and that sort of transition has already occurred. You're totally right looking at the numbers. 51% of their revenue comes from diabetes-focused GLP-1 drugs, and an additional 18% from obesity-related GLP-1. So 69% of their revenue comes from semaglutide or liraglutide. I mean, it's crazy. That happened in a decade.